CagriSema
A Novo Nordisk investigational combination of cagrilintide and semaglutide, designed to pair amylin and GLP-1 pathways in obesity.
Also appears in: Hormone
This compound has a genuine development or study trail, but it is not an approved routine drug.
Primary lane: Weight Loss. Also surfaces under Hormone for browsing and discovery.
No major aliases are tracked for this profile yet.
No FDA label signal · 30 trials · 34 PubMed results
What CagriSema is
CagriSema is Novo Nordisk’s investigational obesity combination that pairs cagrilintide with semaglutide.
Why it matters
It is one of the highest-profile examples of the industry trying to combine amylin and GLP-1 biology in a single branded program rather than selling the components as separate ideas.
Regulatory context
CagriSema is not FDA approved. It remains a late-stage investigational obesity drug program.
Practical reading note
CagriSema matters because it helps connect the standalone peptide pages to the combination products that people actually end up hearing about in headlines and social media.